Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5CNS 5NET 3Head & Neck 1Genitourinary 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Multiple Endocrine Neoplasia 1Kidney Neoplasms 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine phosphate 1cabozantinib 1atezolizumab 1Nivolumab 1Ipilimumab 1Interleukin-13 1Genetic Testing 1Fluorodeoxyglucose F18 1Cyclophosphamide 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × gallium Ga 68 dotatate × Head & Neck × Clear all
NCT06479811 2026-04-28

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
120 enrolled
CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡